&w=3840&q=100)
Ericsson Antenna System expands local manufacturing footprint in India
Subhayan Chakraborty New Delhi
Listen to This Article
Ericsson Antenna System (EAS) is expanding its local manufacturing footprint in India and plans to localise 100 per cent of passive antenna production for the Indian market by June, the telecom gear maker said on Tuesday. The move will be executed in collaboration with VVDN Technologies.
Beyond meeting domestic needs, a significant portion of antennas manufactured in India will be exported, establishing the country as a strategic hub within Ericsson's global supply chain, the Stockholm-based company stressed. Antennas transmit and receive electromagnetic radio waves between communication devices and are a crucial component in the telecom equipment value chain.
Beyond towers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
17 minutes ago
- The Hindu
Business partnerships, direct flights on cards to boost Kazakhstan, Telangana ties
Hyderabad-based MSN Laboratories has entered into an MoU with Kazakh Invest for establishing a pharmaceutical manufacturing facility in Kazakhstan. A few other entities were also exploring business opportunities in Kazakhstan. Discussions are under way to launch direct flights between Hyderabad and Almaty, Honorary Consul of Kazakhstan Nawab Mir Nasir Ali Khan informed Telangana Deputy Chief Minister Mallu Bhatti Vikramarka during a meeting. The Deputy Chief Minister assured government of Telangana's support for such initiatives. He also accepted Mr. Khan's formal invitation to visit Kazakhstan, a release on the meeting aimed at deepening the economic and cultural ties said. The focus was on expanding bilateral trade, healthcare, education and connectivity. Mr. Khan said he recently met Head of Airline Marketing and Route Development at GMR Airport Ananda Acharya to initiate the possibility of launching a direct air connectivity as that would boost tourism, trade and cultural exchange. He also informed Mr. Bhatti about discussions with CEO of Apollo Hospitals Group Srinivas Rao for setting up a medical education institution and a world-class hospital in Kazakhstan.
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
Swiggy unveils ‘99 store' What it is and how it works Budget-friendly meals
Swiggy unveils '99 store' | What it is and how it works | Order food online | Budget-friendly meals Swiggy has introduced a new '99 Store' feature on its app, offering single-serve meals at just ₹99 in over 175 Indian cities. The is designed to attract Gen Z users and budget-conscious customers. Here's everything you need to know about Swiggy's most value-driven food delivery offering yet.
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up
Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has said it is prepared to address an anticipated decline in sales in the United States in FY26 through a combination of organic and inorganic strategies. In a joint message to stakeholders, DRL's chairman K Satish Reddy and co-chairman and managing director G V Prasad said one of the company's key products in the US will face increased competition starting February 2026, likely leading to a fall in sales and profits. 'We have been preparing for this through FY25, through a combination of organic and inorganic strategies,' the message added. DRL stated that in FY26, it aims to grow and strengthen its core businesses and enhance value through portfolio management and strategic differentiation. The company also plans to scale its presence in consumer healthcare, innovative therapies and biosimilars, introduce new revenue streams through acquisitions and partnerships, and streamline structural costs to cushion the impact. For FY25, DRL recorded a 17 per cent rise in total revenue from operations—from ₹27,916 crore in FY24 to ₹32,554 crore. According to the company's investor presentation, North America contributed 45 per cent of DRL's full-year revenue. 'In the US, growth was steady and matched market pace, supported by new launches, Lenalidomide sales, and a stable base business,' the company noted in its annual report filed with the exchanges. The drugmaker has been targeting a larger share of the US market through a dual-track strategy: reinforcing its core business of branded generics, biosimilars and over-the-counter (OTC) drugs, while also investing in growth areas such as consumer healthcare, biosimilars and novel molecules including new chemical entities (NCEs) and CAR-T therapies. 'Leveraging our distribution capabilities, we entered into a nutrition venture with Nestlé in India, received US rights for Cyclophosphamide from Ingenus, and launched Galvus (anti-diabetes) in Russia,' DRL said. The company also highlighted that its subsidiary, Aurigene, received US FDA approval for two oncology assets—AUR110 for solid tumours and AUR112 for lymphoid malignancies—and has filed for approval of the osteoporosis drug Denosumab in the US and Europe. 'These initiatives are in line with our strategy to address issues of availability and accessibility of affordable innovation through in-house and collaborative efforts,' the annual report stated. On Wednesday, DRL's share closed 0.41 per cent lower at ₹1,271.75 apiece on the Bombay Stock Exchange (BSE).
